Study identifier:D0540C00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-022574-14
CTIS identifier:N/A
A single-blind, randomized, placebo controlled, parallel-group, adaptive-design study to investigate the impact of dose and dosing frequency of AZD8848 administered intranasally for up to 7 days, on the biomarker
Healthy Volunteers
Phase 1
Yes
AZD8848, Placebo
All
55
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Aug 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: 1 Placebo given once daily on 7 days | Drug: Placebo Placebo |
Experimental: 2 Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6 | Drug: AZD8848 The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo. Drug: Placebo Placebo |
Experimental: 3 Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6. | Drug: AZD8848 The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo. Drug: Placebo Placebo |
Experimental: 4 Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6. | Drug: AZD8848 The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo. Drug: Placebo Placebo |
Experimental: 5 Active treatment once daily on 7 days | Drug: AZD8848 The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo. |